切换至 "中华医学电子期刊资源库"
高级检索
中华肺部疾病杂志(电子版)

中华肺部疾病杂志(电子版) ›› 2020, Vol. 13 ›› Issue (01) : 54 -58. doi: 10.3877/cma.j.issn.1674-6902.2020.01.011

论著

探讨TGFβ1、PDGF、VEGF对特发性肺纤维化诊断及病情评估的临床意义
孙莹1, 宋晓萍1, 孙伟1,†()   
  1. 1. 116001　辽宁，大连大学附属中山医院呼吸一科
  • 收稿日期:2019-10-11 出版日期:2020-02-25
  • 通信作者: 孙伟
  • 基金资助:
    大连市卫健委专项基金(1811114)

Clinical significance of transforming growth factor beta 1, platelet-derived growth factor and vascular endothelial growth factor in diagnosis and evaluation of idiopathic pulmonary fibrosis

ying Sun1, yang Peifu1, wei Sun1,†()   

  1. 1. Department of Respiratory Medicine, Affiliated Zhongshan Hospital, Dalian University, Dalian 116001, China
  • Received:2019-10-11 Published:2020-02-25
  • Corresponding author: wei Sun
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

孙莹, 宋晓萍, 孙伟. 探讨TGFβ1、PDGF、VEGF对特发性肺纤维化诊断及病情评估的临床意义[J]. 中华肺部疾病杂志(电子版), 2020, 13(01): 54-58.

ying Sun, yang Peifu, wei Sun. Clinical significance of transforming growth factor beta 1, platelet-derived growth factor and vascular endothelial growth factor in diagnosis and evaluation of idiopathic pulmonary fibrosis[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2020, 13(01): 54-58.

目的

探讨分泌转化生长因子-β、血小板衍生生长因子、血管内皮生长因子在特发性肺纤维化(IPF)患者支气管肺泡灌洗液(BALF)和血清中的表达水平及评估病情进展的临床意义。

方法

选择2014年1月至2018年12月在我院呼吸科诊治的35例IPF患者作为观察组，18例肺结节病患者(Ⅰ期)作为对照组；采用免疫印迹观察TGFβ1、PDGF、VEGF在IPF患者血清中是否存在表达；用酶联免疫吸附法(ELISA)观察2组患者BALF和血清中TGFβ1、PDGF、VEGF的表达水平；最后分析IPF患者BALF和血清中TGFβ1、PDGF、VEGF表达水平与肺功能及血氧饱和度的相关性。

结果

TGFβ1、PDGF、VEGF细胞印在IPF患者血清存在表达；与对照组相比，BALF及血清中的TGFβ1、PDGF、VEGF表达上调(P<0.05)；IPF组患者BALF及血清中TGFβ1、PDGF、VEGF表达水平与肺功能中FVC%、FEV1%和DLCO%呈负性相关(P<0.05)；与血氧饱和度也呈显著负相关(P<0.05)。

结论

IPF患者BALF和血清中TGFβ1、PDGF、VEGF的表达水平明显升高；TGFβ1、PDGF、VEGF与患者的肺功能及血氧饱和度呈负相关，可作为评估IPF患者病情的临床评价指标。

关键词: 特发性肺纤维化, 分泌转化生长因子-β, 血小板衍生生长因子, 血管内皮生长因子
Objective

To investigate the expression and clinical significance of transforming growth factor beta 1 (TGFβ1), platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) in the patients with idiopathic pulmonary fibrosis (IPF).

Methods

A total of 35 IPF patients were selected who were admitted in our hospital from January 2014 to December 2018 as the IPF group and 18 patients with pulmonary sarcoidosis of Stage Ⅰ who were admitted in our hospital at the same period were taken as the control group. Firstly, Western blotting method was employed to observe whether the TGFβ1, PDGF and VEGF expressed in the serum. Secondly, the expression levels of TGFβ1, PDGF and VEGF in the bronchoalveolar lavage fluid (BALF) and in the serum were detected by enzyme-linked immunosorbent assay. Finally, the correlations of TGFβ1, PDGF and VEGF with the pulmonary functions and the blood oxygen saturation were analyzed.

Results

Expression of TGFβ1, PDGF and VEGF exists in the serum of the IPF patients. The expression levels of TGFβ1, PDGF and VEGF in the BALF and in the serum were significantly higher in the IPF group than the control group (P<0.05). The expression levels of TGFβ1, PDGF and VEGF in the BALF and in the serum were negatively correlated with FVC%, FEV1% and DLCO%pred in the IPF group, while they were negatively correlated with the degree of blood oxygen saturation.

Conclusion

The expression levels of TGFβ1, PDGF and VEGF in the serum and in the BALF increase in the IPF patients. They are negatively correlated with the pulmonary functions and the degree of blood oxygen saturation, which can be used as a clinical effective marker for disease monitoring and severity evaluation.

Key words: Idiopathic pulmonary fibrosis, Transforming growth factor-β, Platelet derived growth factor, Vascular endothelial growth factor
图1 结节病与IPF的CT影像学表现
图2 免疫印迹检测各组TGFβ1、PDGF、VEGF的表达水平
表1 两组患者BALF液中TGFβ1、PDGF、VEGF的表达变化
组　别 例数 BALF液
TGF-β1(μ/ml) PDGF(μ/ml) VEGF(μ/ml)
IPF组 35 523.27±285.68 465.01±187.71 329.08±107.71
对照组 18 206.03±109.87 185.01±123.71 129.01±106.09
t值   5.013 4.203 3.403
P值   0.000 0.000 0.000
表2 两组患者血清中TGFβ1、PDGF、VEGF的表达变化
组　别 例数 血清
TGF-β1(μ/ml) PDGF(μ/ml) VEGF(μ/ml)
IPF组 35 823.27±405.76 700.78±377.54 590.12±221.23
对照组 18 346.03±219.87 290.01±213.06 227.01±195.29
t值   7.513 6.783 5.723
P值   0.000 0.000 0.000
表3 IPF患者TGFβ1、PDGF、VEGF与肺功能检查及血氧分压的相关性
指　标 FEV1% FVC% DLCO% PaO2(mmHg)
γ P γ P γ P γ P
BALF                
TGF-β1 -0.674 0.000 -0.523 0.000 -0.411 0.000 -2.589 0.000
PDGF -0.576 0.000 -0.489 0.000 -0.401 0.000 -1.109 0.000
VEGF -0.441 0.000 -0.378 0.000 -0.281 0.000 -0.351 0.000
血清                
TGF-β1 -0.805 0.000 -0.752 0.000 -0.602 0.000 -0.619 0.000
PDGF -0.685 0.000 -0.616 0.000 -0.495 0.000 -0.551 0.000
VEGF -0.521 0.000 -0.508 0.000 -0.389 0.000 -0.267 0.000
1
崔社怀. 特发性肺间质纤维化的回顾和展望[J/CD]. 中华肺部疾病杂志(电子版), 2010, 3(1): 4-5.
2
Wu Q, Zhou Y, Feng FC, et al. Effectiveness and safety of Chinese medicine for Idiopathic pulmonary fibrosis: A systematic review and meta-analysis[J]. Chin J integr Med, 2019, 25(10): 778-784.
3
Marshall DC, Salciccioli JD, Shea BS, et al. Trends in mortality from idiopathic pulmonary fibrosis in the European Union: an Observational study of the WHO mortality database from 2001-2013[J]. EurRespir J, 2018, 51(1): 1701603.
4
Gannon W, Lederer DJ, Biscotti M, et al. Outcomes and mortality prediction model of critically ill adults with acute respiratory failure and interstitial lung disease[J]. Chest, 2018, 3692(18): 30078-30073.
5
Kreuter M, Costabel U, Richeldi L, et al. Statin therapy and outcomes in trials of Nintedanib in Idiopathic pulmonary fibrosis[J]. Respiration, 2018, 95(5): 317-326.
6
Gabasa M, Duch P, Jorba I, et al. Epithelial contribution to the profibrotic stiff microenvironment and myofibroblast population in lung fibrosis[J]. Mol Biol Cell, 2017, 28(26): 3741-3755.
7
Li LC, Xu L, Hu Y, et al. Astragaloside Ⅳ improves bleomycin-induced pulmonary fibrosis in rats by attenuating extracellular matrix deposition[J]. Front Pharmacol, 2017, 8(8): 513.
8
Nyp MF, Mabry SM, Navarro A, et al. Lung epithelial-specific TRIP-1 overexpression maintains epithelial integrity during hyperoxia exposure[J]. Physiol Rep, 2018, 6(5): doi: 10.14814/phy2.13585.
9
Zheng S, Wang Q, D′Souza V, et al. Resolvin D stimulates epithelial wound repair andinhibitsTGF-β-induced EMT whilst reducing fibroproliferation and collagen production[J]. Lab Invest, 2018, 98(1): 130-140.
10
Kishi M, Aono Y, Sato S, et al. Blockade of platelet-derived growth factor receptor-β，not receptor-α ameliorates bleomycin-induced pulmonary fibrosis in mice[J]. PLoS One, 2018, 13(12): e0209786.
11
Barratt SL, Blythe T, Ourradi K, et al. Effects of hypoxia and hyperoxia on the differential expression of VEGF-A isoforms and receptors in idiopathic pulmonary Fibrosis (IPF)[J]. Respir Res, 2018, 19(1): 9.
12
Povedano JM, Martinez P, Serrano R, et al. Therapeutic effects of telomerase in mice with pulmonary fibrosis induced by damage to the lungs and short telomeres[J]. Elife, 2018, 30(7): e31299.
13
Torrisi SE, Palmucci S, Stefano A, et al. Assessment of survival in patients with idiopathic pulmonary fibrosis using quantitative HRCT indexes[J]. Multidiscip Respir Med, 2018, 1(13): 43.
14
Yu SH, Liu LJ, Lv B, et al. Inhibition of bleomycin-induced pulmonary fibrosis by bone marrow-derived mesenchymal stem cells might be mediated by decreasing MMP9, TIMP-1, INF-γ and TGF-β[J]. Cell Biochem Funct, 2015, 33(6): 356-366.
15
Ronan N, Bennett DM, Khan KA, et al. Tissue and Bronchoalveolar lavage biomarkers in idiopathic pulmonary fibrosis patients on pirfenidone[J]. Lung, 2018, 196(5): 543-552.
16
Alsumrain M, De Giacomi F, Nasim F, et al. Combined pulmonary fibrosis and emphysema as a clinicoradiologic entity: Characterization of presenting lung fibrosis and implications for survival[J]. Respir Med, 2019, 146: 106-112.
17
Ramos-Rossy J, Cantres-Fonseca O, Arzon-Nieves G, et al. Misleading diagnosis of idiopathic pulmonary fibrosis: A clinical concern[J]. Fed Pract, 2018, 35(2): 40-42.
18
Xie T, Liang J, Geng Y, et al. MicroRNA-29c prevents pulmonary fibrosis by regulating epithelial cell renewal and apoptosis[J]. Am J Respir Cell Mol Biol, 2017, 57(6): 721-732.
19
Kropski JA, Blackwell TS. Progress in understanding and treating Idiopathic Pulmonary Fibrosis[J]. Annu Rev Med, 2019, 27(70): 211-224.
20
Kolilekas L, Papiris S, Bouros D. Existing and emerging treatments for idiopathic pulmonary fibrosis[J]. Expert Rev Respir Med, 2019, 13(3): 229-239.
[1] 邵小丽, 林燕, 张玲玲, 韩亚琴. 超声引导下子宫肌瘤注射聚桂醇硬化术联合术后米非司酮治疗临床疗效分析[J]. 中华妇幼临床医学杂志(电子版), 2024, 20(03): 353-360.
[2] 黄福, 王黔, 金相任, 唐云川. VEGFR2、miR-27a-5p在胃癌组织中的表达与临床病理参数及预后的关系研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(05): 558-561.
[3] 周璇, 谢莉, 邹娟. 尼达尼布对特发性肺纤维化肺功能、肺纤维化程度及PDGF、PGE2、TGF-β1的影响[J]. 中华肺部疾病杂志(电子版), 2024, 17(03): 368-372.
[4] 邱凌霄, 王创业, 卿斌, 刘锦程, 张鑫烨, 武文娟, 邢德冰, 郭亮, 徐智, 王斌. 基于转录组学筛选特发性肺纤维化的枢纽基因和信号通路[J]. 中华肺部疾病杂志(电子版), 2024, 17(02): 212-217.
[5] 吴沛玲, 娄月妍, 张洪艳, 陈东方, 刘雪青, 赵丽芳, 薛姗, 蒋捍东. 线粒体相关基因在特发性肺纤维化中的分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(02): 178-184.
[6] 庞丹, 孙刚, 伊乐, 丁立云, 钟美艳, 张杰, 于婷婷, 郭乐峰. 血清HIF-1α、VEGF、Flt-1的检测对ARDS的预后及临床意义[J]. 中华肺部疾病杂志(电子版), 2024, 17(01): 127-130.
[7] 拉周措毛, 山春玲, 李国蓉, 华毛. 青海西宁地区IPF-LC的病理类型及临床特征分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(01): 25-29.
[8] 暴静, 吴霞, 田雅萍, 尹钢. 维生素D3联合孟鲁司特钠治疗支气管哮喘对血清VEGF、TGF-β1及肺功能的影响[J]. 中华肺部疾病杂志(电子版), 2024, 17(01): 63-67.
[9] 谷先勇, 徐娟. 特发性肺纤维化合并T2DM炎症水平与预后相关性分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(05): 721-723.
[10] 芦丹, 杨硕, 刘旭. VEGF、HMGB1、hs-CRP/Alb在AECOPD伴呼吸衰竭中的变化及预后分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 532-534.
[11] 朱迎, 赵征, 许达, 陆录, 殷保兵. 免疫检查点抑制剂治疗肝细胞癌的进展与展望[J]. 中华肝脏外科手术学电子杂志, 2024, 13(01): 5-10.
[12] 刘涵, 沈强, 张蓝月, 陈健. 糖尿病视网膜病变分子生物标志物的研究进展[J]. 中华眼科医学杂志(电子版), 2023, 13(06): 376-380.
[13] 杨金涓, 夏建平. 糖尿病性黄斑水肿患者基线房水细胞因子水平评估血管内皮生长因子疗效的临床研究[J]. 中华眼科医学杂志(电子版), 2023, 13(06): 350-355.
[14] 宋建波, 韩俊伟, 周敏, 温红萍. 血管内皮生长因子受体酪氨酸激酶抑制剂致蛋白尿风险的荟萃分析[J]. 中华临床医师杂志(电子版), 2023, 17(12): 1297-1303.
[15] 颜凡辉, 赵明俐, 李颖, 郭方明, 詹景冬, 赵英杰, 王阳, 张艳芬, 赵笑梅. 急性冠脉综合征患者冠脉血管病变程度与血清TNF-α、VEGF水平相关性研究[J]. 中华诊断学电子杂志, 2023, 11(03): 158-164.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号